ESMO Open最新文献

{"title":"12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation","authors":"Z. Ianniello, E. Quijano, D.A. Colón-Ríos, M. Rackear, P.M. Glazer","doi":"10.1016/j.esmoop.2026.106115","DOIUrl":"10.1016/j.esmoop.2026.106115","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106115"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"32P Whole-slide histopathology embeddings enable non-genomic HER2 biomarker prediction in esophageal adenocarcinoma","authors":"K. Nijjer , A. Ahmed","doi":"10.1016/j.esmoop.2026.106136","DOIUrl":"10.1016/j.esmoop.2026.106136","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106136"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"98P Optimizing treatment for CDK4/6 inhibitor-resistant breast cancer using patient-derived models","authors":"B. Policastro , N. Nissen , M.K. Jakobsen , S. Ehmsen , O.L. Gammelgaard , F. Rosengren , L.E. Johansen , J. Staaf , H.J. Ditzel , C.L. Alves","doi":"10.1016/j.esmoop.2026.106240","DOIUrl":"10.1016/j.esmoop.2026.106240","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106240"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"111P EGFR and MET mRNA overexpression in non-small cell lung cancer: Prevalence and sensitivity to targeted therapies","authors":"S. Garcia-Roman , C. Aguado , E. Marin , C. Mayo de Las Casas , M. Garzón-Ibáñez , N. Jordana Ariza , R. Roman , E. Aldeguer , S. Muñoz , I. Sánchez , R. Reyes , M.F. García Casabal , R. Rosell , M.A. Molina-Vila","doi":"10.1016/j.esmoop.2026.106253","DOIUrl":"10.1016/j.esmoop.2026.106253","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106253"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE","authors":"J. Fayette ,&nbsp;C. Cropet ,&nbsp;C. Toullec ,&nbsp;M. Burgy ,&nbsp;A. Bruyas ,&nbsp;C. Sire ,&nbsp;A. Lagrange ,&nbsp;F. Clatot ,&nbsp;M. Vinches ,&nbsp;M. Iacob ,&nbsp;L. Martin ,&nbsp;M.-C. Kaminsky ,&nbsp;D. Vansteene ,&nbsp;S. Salas ,&nbsp;A. Champagnac ,&nbsp;P. Saintigny ,&nbsp;J. Gautier ,&nbsp;D. Pérol ,&nbsp;J. Bourhis","doi":"10.1016/j.esmoop.2026.106946","DOIUrl":"10.1016/j.esmoop.2026.106946","url":null,"abstract":"<div><h3>Background</h3><div>Pembrolizumab, combined with platinum-5-FU or as a monotherapy, is the standard treatment of patients with recurrent and/or metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC). This treatment is used exclusively in programmed death-ligand 1 (PD-L1)-positive patients in Europe, whereas it is used in the USA regardless of PD-L1 status. However, substantial toxicities, notably those related to cisplatin-based chemotherapy, preclude the use of combination therapy in fragile patients. We investigated the efficacy and tolerance of first-line durvalumab combined with weekly carboplatin/paclitaxel in R/M HNSCC patients who were ineligible for cisplatin.</div></div><div><h3>Patients and methods</h3><div>This prospective multicenter single-arm phase II study assessed tolerance in R/M HNSCC patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-1 (run-in phase study feasibility, then cohort A) and ECOG-PS 2 (cohort B), frail, not eligible for standard cisplatin-based chemotherapy. In the first-line, patients received four 28-day chemotherapy cycles (carboplatin AUC2; paclitaxel 80 mg/m² day 1, 8, and 15) combined with durvalumab 1500 mg every 4 weeks for 12 months maximum. The primary endpoint was 12-month overall survival (OS) rate based on a Fleming A’Hern design: cohort A, P₀ inefficacy boundary 47%, P₁ target efficacy 65%, at least 38 successes among 64 patients assessable were required for further investigations; cohort B: P₀ 15%; P₁ 35%, at least 10 successes needed among 38 patients to reject the null hypothesis.</div></div><div><h3>Results</h3><div>From 16 May 2019 to 4 March 2021, 64 patients with an ECOG-PS of 1 (cohort A) from 13 French authorized centers (hospital, cancer centers) were included and received study treatments. Cohort B enrolled 40 patients with an ECOG-PS of 2 from 25 Aug 2021 and 9 March 2023 and 39 were assessable. With 40 patients with an ECOG-PS of 0-1 [62.5%, unilateral 95% confidence interval (CI) 51.5%-∞], and 20 patients with an ECOG-PS of 2 (51.3%, unilateral 95% CI 37.1%-∞) alive at 12 months, the study met its primary endpoints.</div></div><div><h3>Conclusions</h3><div>The promising results in frail patients with an ECOG-PS of 0-1 and 2 encourages further investigation of durvalumab with weekly carboplatin/paclitaxel in first-line R/M HNSCC patients in a comparative phase III clinical trial.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106946"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY","authors":"B. Besse ,&nbsp;E. Felip ,&nbsp;B.C. Cho ,&nbsp;T. Takahashi ,&nbsp;K. Politi ,&nbsp;J. Wang ,&nbsp;G. De Castro Jr. ,&nbsp;A. Kowalczyk-Tekiela ,&nbsp;L. Bonanno ,&nbsp;A.S. Muntean ,&nbsp;G. Lo Russo ,&nbsp;J. Fuentes Pradera ,&nbsp;S.H. Kim ,&nbsp;M. Florescu ,&nbsp;P. Chen ,&nbsp;E. Pons-Tostivint ,&nbsp;Y. Chepka ,&nbsp;H. Mann ,&nbsp;J. Rogerio ,&nbsp;P.M. Forde","doi":"10.1016/j.esmoop.2026.106957","DOIUrl":"10.1016/j.esmoop.2026.106957","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106957"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147748465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"56P LncRNAs FENDRR, LINC02560, and SOX21-AS1 regulate chemoresistance in advanced gastric cancer","authors":"I. Riquelme ,&nbsp;P. Pérez-Moreno ,&nbsp;B. Mora ,&nbsp;S. Rivas-Lara ,&nbsp;C. Rojas-Fuentes ,&nbsp;P.E. Yanez Weber ,&nbsp;J.C. Roa ,&nbsp;C. Ili ,&nbsp;P. Brebi","doi":"10.1016/j.esmoop.2026.106162","DOIUrl":"10.1016/j.esmoop.2026.106162","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106162"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"51eP CTC-targeted allogeneic CAR-T cells as a novel approach to early recurrence in operative PDAC","authors":"J. Wierciak ,&nbsp;K. Bak ,&nbsp;N. Wilczynska-Zawal ,&nbsp;K. Rapacz ,&nbsp;H. Plutecka ,&nbsp;Z. Szwalec ,&nbsp;J. Kijowski ,&nbsp;M. Sierzega ,&nbsp;M. Piejko","doi":"10.1016/j.esmoop.2026.106156","DOIUrl":"10.1016/j.esmoop.2026.106156","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106156"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"53P Epigenetic modulation of TERRA by FTSJ3 supports telomerase-mediated oncogenesis","authors":"N. Jette ,&nbsp;J. Price ,&nbsp;O. Abuhussein ,&nbsp;G. Groot ,&nbsp;F. Vizeacoumar ,&nbsp;A. Freywald ,&nbsp;F. Vizeacoumar","doi":"10.1016/j.esmoop.2026.106159","DOIUrl":"10.1016/j.esmoop.2026.106159","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106159"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"126eP Prognostic impact of concomitant genomic alterations in FGFR2-positive cholangiocarcinoma treated with pemigatinib: Molecular analysis of the Italian real-world study","authors":"C. Liguori ,&nbsp;R. Giampieri ,&nbsp;A. Parisi ,&nbsp;M. Niger ,&nbsp;C. Sciortino ,&nbsp;S.K. Garattini ,&nbsp;A. Pastorino ,&nbsp;A. Diana ,&nbsp;A. Palloni ,&nbsp;L. Foltran ,&nbsp;S. Gobba ,&nbsp;M. Mandalà ,&nbsp;M. Bensi ,&nbsp;M. Rimini ,&nbsp;R. Balsano ,&nbsp;D. Lavacchi ,&nbsp;S. Marchetti ,&nbsp;A. Alberti ,&nbsp;C. Vivaldi ,&nbsp;R. Berardi","doi":"10.1016/j.esmoop.2026.106267","DOIUrl":"10.1016/j.esmoop.2026.106267","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106267"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}